Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Martin Diggle

Premium

Proteome Sciences appointed Martin Diggle to its board as a non-executive director. Diggle is a director and partner at Vulpes Investment Management, where he manages the Vulpes Life Sciences Fund, which holds roughly 16 percent of Proteome Sciences’ ordinary shares. He is also a non-executive director of Oxford Biomedica and Chronos Therapeutics.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.